Ares Financial Consulting
LENZ icon

Ares Financial Consulting’s LENZ Therapeutics LENZ Stock Holding History

Ares Financial Consulting’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$73 Hold
19
– – ﹤0.01% 1064
2026
Q2 		$108 Hold
19
– – ﹤0.01% 1121
2026
Q1 		$178 Hold
19
– – ﹤0.01% 1047
2025
Q4 		$304 Buy
+19
New +$554 ﹤0.01% 870

Other funds holding LENZ

Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Ares Financial Consulting's LENZ Position: Q3 2026 in Review

Ares Financial Consulting held its LENZ Therapeutics (LENZ) position steady in Q3 2026 at 19 shares worth $73. The position accounts for ﹤0.01% of the portfolio, ranked #1064.

Ares Financial Consulting first reported a position in LENZ in Q4 2025 and has held it in 4 quarters since. The position peaked at $304 in Q4 2025. 71 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

  • Ares Financial Consulting held 19 shares of LENZ Therapeutics worth $73 as of Q3 2026.
  • Ares Financial Consulting left its LENZ Therapeutics share count unchanged in Q3 2026.
  • LENZ Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #1064 holding.
  • Ares Financial Consulting first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Ares Financial Consulting's LENZ Therapeutics position peaked at $304 in Q4 2025.
  • 71 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.